Do thiazide diuretics confer specific protection against strokes?

被引:22
作者
Messerli, FH
Grossman, E
Lever, AF
机构
[1] Ochsner Clin Fdn, Dept Internal Med, Hypertens Dis Sect, New Orleans, LA 70121 USA
[2] Chaim Sheba Med Ctr, Dept Internal Med D, IL-52621 Tel Hashomer, Israel
[3] Western Infirm & Associated Hosp, Dept Med & Therapeut, Glasgow, Lanark, Scotland
关键词
CONVERTING-ENZYME-INHIBITOR; CORONARY-HEART-DISEASE; CARDIOVASCULAR MORBIDITY; SYSTOLIC HYPERTENSION; ANGIOTENSIN; MORTALITY; INTERVENTION; PREVENTION; THERAPIES; GERBILS;
D O I
10.1001/archinte.163.21.2557
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several large studies have suggested that therapy with thiazide diuretics confers a particular benefit in reducing the risk of strokes that seem to be, at least to some extent, independent of the blood pressure-lowering effect. Such a cerebroprotective effect was documented not only with monotherapy but also when diuretics were used in combination with other drugs. The cerebroprotective effect does not seem to be shared by other drug classes, such as the beta-blockers or the angiotensin-converting enzyme inhibitors, in patients without manifest cardiovascular disease. Since stroke is one of the most devastating sequelae of high blood pressure, our data strongly favor the use of low-dose diuretics either as initial therapy or in combination in all hypertensive patients at risk for cerebrovascular disease.
引用
收藏
页码:2557 / 2560
页数:4
相关论文
共 28 条
[1]   Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) - A randomized controlled trial [J].
Borhani, NO ;
Mercuri, M ;
Borhani, PA ;
Buckalew, VM ;
CanossaTerris, M ;
Carr, AA ;
Kappagoda, T ;
Rocco, MV ;
Schnaper, HW ;
Sowers, JR ;
Bond, MG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (10) :785-791
[2]  
BROWN MJ, 1986, LANCET, V2, P427
[3]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[4]  
Cooper R, 2000, CIRCULATION, V102, P3137
[5]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[6]   Non-AT1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil [J].
Dalmay, F ;
Mazouz, H ;
Allard, J ;
Pesteil, F ;
Achard, JM ;
Fournier, A .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2001, 2 (02) :103-106
[7]   ANGIOTENSIN AT(2) RECEPTOR STIMULATION INCREASES SURVIVAL IN GERBILS WITH ABRUPT UNILATERAL CAROTID LIGATION [J].
FERNANDEZ, LA ;
CARIDE, VJ ;
STROMBERG, C ;
NAVERI, L ;
WICKE, JD .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 24 (06) :937-940
[8]   ANGIOTENSIN-II DECREASES MORTALITY-RATE IN GERBILS WITH UNILATERAL CAROTID LIGATION [J].
FERNANDEZ, LA ;
SPENCER, DD ;
KACZMAR, T .
STROKE, 1986, 17 (01) :82-85
[9]  
Fournier A, 2000, NIEREN HOCHDRUCK, V29, P545
[10]  
Fournier Albert A., 2002, American Journal of Hypertension, V15, p106A